Navigation Links
ULURU Inc. Announces Voting Results of Reconvened Annual Meeting of Stockholders
Date:6/17/2011

ADDISON, Texas, June 17, 2011 /PRNewswire/ -- ULURU Inc. (NYSE AMEX: ULU) today announced that its Annual Meeting of Stockholders was reconvened on June 16, 2011 for the purpose of determining stockholder voting with respect to Proposal No. 3, a proposal to authorize the Board of Directors to amend the Company's Restated Articles of Incorporation at any time prior to July 31, 2011 to effect a reverse stock split of the Company's outstanding common stock at a ratio to be determined by the Board of Directors but not to exceed 15 pre-reverse-split shares into one post-reverse-split share.

As of April 4, 2011, the record date, 87,341,709 shares of common stock were eligible to vote. As of June 16, 2011, approximately 69%, or 60.4 million shares of the Company's outstanding shares have been voted on the charter amendment, and of these shares 46.5 million shares have been voted in favor of the proposal which is in excess of the votes necessary to approve the proposal. The results of the stockholder votes on the third proposal which was considered and voted upon at the reconvened Annual Meeting will be released in a separate 8-K filing.

Kerry P. Gray, the Chairman, Chief Executive Officer and President of ULURU Inc., stated, "We are pleased that our stockholders have voted in favor of this proposal as I believe that implementing the reverse stock split more favorably positions the Company in the financial markets."

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit our website at www.altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), and to favorably positioning the Company in the financial markets. When used in this press release, the words "believe," "expect" and "anticipate" and similar expressions may be indicative of forward-looking statements. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... -- The Corporate Whistleblower Center says, "We are urging ... to call us anytime at 866-714-6466 if they possess ... a substantial scheme to overbill Medicare. We are ... of a medical equipment company if their employer ... practice groups with extra generous incentives to use, or ...
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... Diagnotes, ... as a standard feature on its secure clinical communication platform. The platform allows ... video depending on the type and urgency of a situation. , “We ...
(Date:5/23/2017)... ... 23, 2017 , ... New patients with symptoms of gum disease ... laser gum disease treatments from the doctors at Art of Dentistry, without first receiving ... of the importance of receiving qualified treatment in order to avoid systemic health effects ...
(Date:5/23/2017)... Horeb, WI (PRWEB) , ... May 23, 2017 , ... ... invited to call Dr. Angela Cotey’s practice to schedule an appointment, with or without ... services, and frequently offers pulpotomy treatments to pediatric patients as a healthy alternative to ...
(Date:5/22/2017)... ... May 22, 2017 , ... Dr. Kiya Green, ... with periodontal plastic surgery treatments, including crown lengthening and gum reduction ... these esthetic and functional procedures to help patients improve their oral health, reduce ...
(Date:5/22/2017)... , ... May 22, 2017 , ... “Homeostasis: The Journey ... learning to live with Bipolar 1. Donald Rodriguez takes readers on a rollercoaster ride ... in the dead of winter and to a dark place where Donald considers suicide. ...
Breaking Medicine News(10 mins):